Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: A randomized, controlled study

Lawrence F. Eichenfield, Adelaide A. Hebert, Lawrence A Schachner, Amy S. Paller, Ana Beatris Rossi, Anne W. Lucky

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although acne vulgaris is common in preadolescents (<13 yrs), few acne treatments are currently approved for children. This study assessed the safety and efficacy of tretinoin microsphere gel (TMG) 0.04% pump in children aged 9-11 with acne vulgaris. In this multicenter, randomized, double-blind, vehicle-controlled pilot study, patients applied TMG 0.04% pump or vehicle once daily to the face for 12 weeks. Efficacy measures were changes in facial lesion counts, Investigator Global Evaluation of acne severity using two scales, and Investigator Global Assessment of Improvement from baseline to week 12. Of the 110 patients enrolled, 55 received TMG 0.04% pump, and 55 received vehicle. At week 12, there was significantly greater improvement in the least-squares mean change in noninflammatory lesions with TMG 0.04% than with vehicle (-19.9 vs -9.7, p = 0.04) and a significant difference in Investigator Global Assessment of improvement at week 12 between the children treated with TMG 0.04% pump and those treated with vehicle (p = 0.02), but there were no discernible differences in static acne severity scales. Change from baseline in signs and symptoms of cutaneous irritation were similar between the active and vehicle arms at week 12. This study demonstrated statistically significant differences in the reduction of noninflammatory lesions between TMG 0.04% pump and vehicle in patients aged 9-11 with acne vulgaris. Additional studies are warranted to further characterize the safety and efficacy of TMG 0.04% pump for the treatment of acne in the preadolescent population.

Original languageEnglish
Pages (from-to)598-604
Number of pages7
JournalPediatric Dermatology
Volume29
Issue number5
DOIs
StatePublished - Sep 1 2012

Fingerprint

Acne Vulgaris
Tretinoin
Microspheres
Gels
Research Personnel
Safety
Least-Squares Analysis
Signs and Symptoms
Arm
Skin
Therapeutics
Population

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents : A randomized, controlled study. / Eichenfield, Lawrence F.; Hebert, Adelaide A.; Schachner, Lawrence A; Paller, Amy S.; Rossi, Ana Beatris; Lucky, Anne W.

In: Pediatric Dermatology, Vol. 29, No. 5, 01.09.2012, p. 598-604.

Research output: Contribution to journalArticle

Eichenfield, Lawrence F. ; Hebert, Adelaide A. ; Schachner, Lawrence A ; Paller, Amy S. ; Rossi, Ana Beatris ; Lucky, Anne W. / Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents : A randomized, controlled study. In: Pediatric Dermatology. 2012 ; Vol. 29, No. 5. pp. 598-604.
@article{aa725395ff504fea8f118a65f742bf90,
title = "Tretinoin microsphere gel 0.04{\%} pump for treating acne vulgaris in preadolescents: A randomized, controlled study",
abstract = "Although acne vulgaris is common in preadolescents (<13 yrs), few acne treatments are currently approved for children. This study assessed the safety and efficacy of tretinoin microsphere gel (TMG) 0.04{\%} pump in children aged 9-11 with acne vulgaris. In this multicenter, randomized, double-blind, vehicle-controlled pilot study, patients applied TMG 0.04{\%} pump or vehicle once daily to the face for 12 weeks. Efficacy measures were changes in facial lesion counts, Investigator Global Evaluation of acne severity using two scales, and Investigator Global Assessment of Improvement from baseline to week 12. Of the 110 patients enrolled, 55 received TMG 0.04{\%} pump, and 55 received vehicle. At week 12, there was significantly greater improvement in the least-squares mean change in noninflammatory lesions with TMG 0.04{\%} than with vehicle (-19.9 vs -9.7, p = 0.04) and a significant difference in Investigator Global Assessment of improvement at week 12 between the children treated with TMG 0.04{\%} pump and those treated with vehicle (p = 0.02), but there were no discernible differences in static acne severity scales. Change from baseline in signs and symptoms of cutaneous irritation were similar between the active and vehicle arms at week 12. This study demonstrated statistically significant differences in the reduction of noninflammatory lesions between TMG 0.04{\%} pump and vehicle in patients aged 9-11 with acne vulgaris. Additional studies are warranted to further characterize the safety and efficacy of TMG 0.04{\%} pump for the treatment of acne in the preadolescent population.",
author = "Eichenfield, {Lawrence F.} and Hebert, {Adelaide A.} and Schachner, {Lawrence A} and Paller, {Amy S.} and Rossi, {Ana Beatris} and Lucky, {Anne W.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1111/j.1525-1470.2012.01811.x",
language = "English",
volume = "29",
pages = "598--604",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents

T2 - A randomized, controlled study

AU - Eichenfield, Lawrence F.

AU - Hebert, Adelaide A.

AU - Schachner, Lawrence A

AU - Paller, Amy S.

AU - Rossi, Ana Beatris

AU - Lucky, Anne W.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Although acne vulgaris is common in preadolescents (<13 yrs), few acne treatments are currently approved for children. This study assessed the safety and efficacy of tretinoin microsphere gel (TMG) 0.04% pump in children aged 9-11 with acne vulgaris. In this multicenter, randomized, double-blind, vehicle-controlled pilot study, patients applied TMG 0.04% pump or vehicle once daily to the face for 12 weeks. Efficacy measures were changes in facial lesion counts, Investigator Global Evaluation of acne severity using two scales, and Investigator Global Assessment of Improvement from baseline to week 12. Of the 110 patients enrolled, 55 received TMG 0.04% pump, and 55 received vehicle. At week 12, there was significantly greater improvement in the least-squares mean change in noninflammatory lesions with TMG 0.04% than with vehicle (-19.9 vs -9.7, p = 0.04) and a significant difference in Investigator Global Assessment of improvement at week 12 between the children treated with TMG 0.04% pump and those treated with vehicle (p = 0.02), but there were no discernible differences in static acne severity scales. Change from baseline in signs and symptoms of cutaneous irritation were similar between the active and vehicle arms at week 12. This study demonstrated statistically significant differences in the reduction of noninflammatory lesions between TMG 0.04% pump and vehicle in patients aged 9-11 with acne vulgaris. Additional studies are warranted to further characterize the safety and efficacy of TMG 0.04% pump for the treatment of acne in the preadolescent population.

AB - Although acne vulgaris is common in preadolescents (<13 yrs), few acne treatments are currently approved for children. This study assessed the safety and efficacy of tretinoin microsphere gel (TMG) 0.04% pump in children aged 9-11 with acne vulgaris. In this multicenter, randomized, double-blind, vehicle-controlled pilot study, patients applied TMG 0.04% pump or vehicle once daily to the face for 12 weeks. Efficacy measures were changes in facial lesion counts, Investigator Global Evaluation of acne severity using two scales, and Investigator Global Assessment of Improvement from baseline to week 12. Of the 110 patients enrolled, 55 received TMG 0.04% pump, and 55 received vehicle. At week 12, there was significantly greater improvement in the least-squares mean change in noninflammatory lesions with TMG 0.04% than with vehicle (-19.9 vs -9.7, p = 0.04) and a significant difference in Investigator Global Assessment of improvement at week 12 between the children treated with TMG 0.04% pump and those treated with vehicle (p = 0.02), but there were no discernible differences in static acne severity scales. Change from baseline in signs and symptoms of cutaneous irritation were similar between the active and vehicle arms at week 12. This study demonstrated statistically significant differences in the reduction of noninflammatory lesions between TMG 0.04% pump and vehicle in patients aged 9-11 with acne vulgaris. Additional studies are warranted to further characterize the safety and efficacy of TMG 0.04% pump for the treatment of acne in the preadolescent population.

UR - http://www.scopus.com/inward/record.url?scp=84866414896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866414896&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1470.2012.01811.x

DO - 10.1111/j.1525-1470.2012.01811.x

M3 - Article

C2 - 22712470

AN - SCOPUS:84866414896

VL - 29

SP - 598

EP - 604

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 5

ER -